Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran: a case report.

Piñero-Saavedra M, Castaño MP, Camarero MO, Milla SL.

Blood Coagul Fibrinolysis. 2013 Jul;24(5):576-8. doi: 10.1097/MBC.0b013e32835facc8.

PMID:
23511900
2.

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators.

N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697.

3.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

4.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group.

N Engl J Med. 2009 Dec 10;361(24):2342-52. doi: 10.1056/NEJMoa0906598. Epub .

5.

Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.

[No authors listed]

Prescrire Int. 2012 Feb;21(124):33-6. Review.

PMID:
22413715
6.

Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?

Hughes PJ, Freeman MK.

Consult Pharm. 2012 Jun;27(6):445-52. doi: 10.4140/TCP.n.2012.445.

PMID:
22698551
7.

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.

Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.

8.

Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.

Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, Crawford T, Suwanagool A, Sinno M, Carrigan T, Kennedy R, Saint-Phard W, Yokokawa M, Good E, Bogun F, Pelosi F Jr, Morady F, Oral H.

Heart Rhythm. 2013 Apr;10(4):483-9. doi: 10.1016/j.hrthm.2012.12.011. Epub 2012 Dec 11.

PMID:
23237911
9.
10.

Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.

Ali A, Bailey C, Abdelhafiz AH.

Age Ageing. 2012 Sep;41(5):681-4. doi: 10.1093/ageing/afs017. Epub 2012 Feb 28.

11.

The use of dabigatran immediately after atrial fibrillation ablation.

Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA.

J Cardiovasc Electrophysiol. 2012 Mar;23(3):264-8. doi: 10.1111/j.1540-8167.2011.02175.x. Epub 2011 Sep 28.

PMID:
21955008
12.

Warfarin versus dabigatran: comparing the old with the new.

Abraham ME, Marcy TR.

Consult Pharm. 2012 Feb;27(2):121-4. doi: 10.4140/TCP.n.2012.121. Review.

PMID:
22330953
13.

Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

Escobar C, Barrios V, Jimenez D.

Cardiovasc Ther. 2010 Oct;28(5):295-301. doi: 10.1111/j.1755-5922.2010.00216.x. Epub 2010 Aug 16. Review.

PMID:
20718760
14.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
15.

Rash associated with dabigatran etexilate.

To K, Reynolds C, Spinler SA.

Pharmacotherapy. 2013 Mar;33(3):e23-7. doi: 10.1002/phar.1203. Epub 2013 Feb 11.

PMID:
23400964
16.

Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl.

Buyuktiryaki AB, Bezirganoglu H, Sahiner UM, Yavuz ST, Tuncer A, Kara A, Sackesen C.

Australas J Dermatol. 2012 Nov;53(4):274-7. doi: 10.1111/j.1440-0960.2012.00887.x. Epub 2012 Apr 24.

PMID:
22524313
17.

Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.

Atay JK, Fiumara K, Piazza G, Fanikos J, Goldhaber SZ.

Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):181-4. doi: 10.1177/1076029611416642. Epub 2011 Aug 25.

PMID:
21873358
18.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
19.

Treatment of venous thromboembolism with dabigatran.

Schulman S.

Curr Opin Pulm Med. 2012 Sep;18(5):410-5. doi: 10.1097/MCP.0b013e32835466eb. Review.

PMID:
22617811
20.

Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.

Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A.

J Am Coll Cardiol. 2012 Mar 27;59(13):1168-74. doi: 10.1016/j.jacc.2011.12.014. Epub 2012 Feb 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk